EditorialPublished 30 Jun 2024
Exploring the Role of PARP Inhibitors in Ovarian and Endometrial Cancers
Department of Obstetrics and Gynecology, University of Kentucky, USA
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Poly(ADP-ribose) polymerase (PARP) inhibitors have revolutionized the treatment landscape for ovarian and endometrial cancers, particularly in patients with specific genetic vulnerabilities. This article explores the mechanisms of action of PARP inhibitors, emphasizing their role in exploiting defects in DNA repair pathways, such as those seen in BRCA1 and BRCA2 mutations. In ovarian cancer, PARP inhibitors like olaparib, niraparib, and rucaparib have demonstrated significant efficacy in both treatment and maintenance settings, leading to improved progression-free survival. In endometrial cancer, the potential of PARP inhibitors is being investigated, particularly in patients with homologous recombination deficiency (HRD) and those with Lynch syndrome [1]. Ongoing clinical trials are exploring combination therapies to enhance treatment outcomes, as well as strategies to overcome resistance to PARP inhibition. As the understanding of tumor biology evolves, the integration of PARP inhibitors into personalized treatment regimens holds promise for improving patient outcomes in gynecologic malignancies. This review highlights the current state of PARP inhibitor therapy in ovarian and endometrial cancers and discusses future directions for research and clinical application
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInsights in Gynecologic Oncology
- SubjectOncology & Cancer
- SubjectReproductive Medicine & Gynaecology
- BylineArticles whose byline prints “Swiecki Allison”